Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia
<p dir="ltr">In this study, we investigated the prevalence of sexual dysfunction among males with advanced chronic kidney disease and the effect of treating hyperprolactinemia among these patients. In this prospective study, patients were assessed with history, physical examination,...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , |
| Published: |
2021
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513565189210112 |
|---|---|
| author | Haitham Elbardisi (14058048) |
| author2 | Ahmad Majzoub (14058045) Christiana Daniel (14779213) Fadwa Al.Ali (14779216) Mohamed Elesnawi (14779219) Kareim Khalafalla (14148807) Ashok Agarwal (325619) Ralf Henkel (8192964) Alia Alattar (14779222) Ibrahim Al‐Emadi (14779225) Mohamed Arafa (14058042) |
| author2_role | author author author author author author author author author author |
| author_facet | Haitham Elbardisi (14058048) Ahmad Majzoub (14058045) Christiana Daniel (14779213) Fadwa Al.Ali (14779216) Mohamed Elesnawi (14779219) Kareim Khalafalla (14148807) Ashok Agarwal (325619) Ralf Henkel (8192964) Alia Alattar (14779222) Ibrahim Al‐Emadi (14779225) Mohamed Arafa (14058042) |
| author_role | author |
| dc.creator.none.fl_str_mv | Haitham Elbardisi (14058048) Ahmad Majzoub (14058045) Christiana Daniel (14779213) Fadwa Al.Ali (14779216) Mohamed Elesnawi (14779219) Kareim Khalafalla (14148807) Ashok Agarwal (325619) Ralf Henkel (8192964) Alia Alattar (14779222) Ibrahim Al‐Emadi (14779225) Mohamed Arafa (14058042) |
| dc.date.none.fl_str_mv | 2021-06-05T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1111/and.14135 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Endocrine_contribution_to_the_sexual_dysfunction_in_patients_with_advanced_chronic_kidney_disease_and_the_role_of_hyperprolactinemia/22258435 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Reproductive medicine end-stage renal disease erectile dysfunction hyperprolactinemia hypogonadism premature |
| dc.title.none.fl_str_mv | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">In this study, we investigated the prevalence of sexual dysfunction among males with advanced chronic kidney disease and the effect of treating hyperprolactinemia among these patients. In this prospective study, patients were assessed with history, physical examination, hormonal assessment, and two questionnaires, IIEF and AIPE. Patients with hyperprolactinemia received treatment with cabergoline 0.5 mg once per week for 6 months and were re-evaluated. A total of 102 patients were included in this study, 75 (73.53%) were on hemodialysis, 13 (12.75%) on peritoneal dialysis and 14 (13.73%) on medical treatment alone. Ninety (88.24%) patients had premature ejaculation, 85 (83.33%) had anything from mild-to-moderate-to-severe erectile dysfunction. The incidence of hypogonadism and hyperprolactinemia was 34.4%. Patients treated with cabergoline (<i>n</i> = 26) showed a significant increase in LH levels (<i>p</i> = .003) and a significant decrease in prolactin levels (<i>p</i> = .003). Testosterone levels and the incidence of erectile dysfunction or premature ejaculation did not improve significantly. There is a high incidence of sexual dysfunction among patients. Treatment of hyperprolactinemia is effective in correcting prolactin levels, but does not improve erectile dysfunction or premature ejaculation. Therefore, treating hyperprolactinemia is not an overall effective treatment for erectile dysfunction in these patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Andrologia<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1111/and.14135" target="_blank">http://dx.doi.org/10.1111/and.14135</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_13a0ace29a3fcb119f70ae976d3aa0bc |
| identifier_str_mv | 10.1111/and.14135 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22258435 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemiaHaitham Elbardisi (14058048)Ahmad Majzoub (14058045)Christiana Daniel (14779213)Fadwa Al.Ali (14779216)Mohamed Elesnawi (14779219)Kareim Khalafalla (14148807)Ashok Agarwal (325619)Ralf Henkel (8192964)Alia Alattar (14779222)Ibrahim Al‐Emadi (14779225)Mohamed Arafa (14058042)Biomedical and clinical sciencesClinical sciencesReproductive medicineend-stage renal diseaseerectile dysfunctionhyperprolactinemiahypogonadismpremature<p dir="ltr">In this study, we investigated the prevalence of sexual dysfunction among males with advanced chronic kidney disease and the effect of treating hyperprolactinemia among these patients. In this prospective study, patients were assessed with history, physical examination, hormonal assessment, and two questionnaires, IIEF and AIPE. Patients with hyperprolactinemia received treatment with cabergoline 0.5 mg once per week for 6 months and were re-evaluated. A total of 102 patients were included in this study, 75 (73.53%) were on hemodialysis, 13 (12.75%) on peritoneal dialysis and 14 (13.73%) on medical treatment alone. Ninety (88.24%) patients had premature ejaculation, 85 (83.33%) had anything from mild-to-moderate-to-severe erectile dysfunction. The incidence of hypogonadism and hyperprolactinemia was 34.4%. Patients treated with cabergoline (<i>n</i> = 26) showed a significant increase in LH levels (<i>p</i> = .003) and a significant decrease in prolactin levels (<i>p</i> = .003). Testosterone levels and the incidence of erectile dysfunction or premature ejaculation did not improve significantly. There is a high incidence of sexual dysfunction among patients. Treatment of hyperprolactinemia is effective in correcting prolactin levels, but does not improve erectile dysfunction or premature ejaculation. Therefore, treating hyperprolactinemia is not an overall effective treatment for erectile dysfunction in these patients.</p><h2>Other Information</h2><p dir="ltr">Published in: Andrologia<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1111/and.14135" target="_blank">http://dx.doi.org/10.1111/and.14135</a></p>2021-06-05T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1111/and.14135https://figshare.com/articles/journal_contribution/Endocrine_contribution_to_the_sexual_dysfunction_in_patients_with_advanced_chronic_kidney_disease_and_the_role_of_hyperprolactinemia/22258435CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222584352021-06-05T06:00:00Z |
| spellingShingle | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia Haitham Elbardisi (14058048) Biomedical and clinical sciences Clinical sciences Reproductive medicine end-stage renal disease erectile dysfunction hyperprolactinemia hypogonadism premature |
| status_str | publishedVersion |
| title | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia |
| title_full | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia |
| title_fullStr | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia |
| title_full_unstemmed | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia |
| title_short | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia |
| title_sort | Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia |
| topic | Biomedical and clinical sciences Clinical sciences Reproductive medicine end-stage renal disease erectile dysfunction hyperprolactinemia hypogonadism premature |